Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous tocilizumab in active rheumatoid arthritis
2013-000359-42Phase 3Completed
- Sponsor
- Roche
- Start
- Aug 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of tocilizumab in rheumatoid arthritis (RA) (2 arms), sponsored by Roche. Primary endpoint: DAS28 remission at Week 24. Started Aug 2013; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2013-000359-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000359-42.